Evidence map›Paper›PMID 33074365›Full record

ReviewInfection2021

Ceftazidime/avibactam and ceftolozane/tazobactam for the treatment of extensively drug-resistant Pseudomonas aeruginosa post-neurosurgical infections: three cases and a review of the literature.

Marianna Meschiari, Iacopo Franconi, Erica Bacca, Vincenzo Bianco, Gabriella Orlando, Gianluca Cuomo, Andrea Bedini, Cristina Mussini

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Infection, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Marianna MeschiariInfectious Diseases Unit, Azienda Ospedaliero-Universitaria Policlinico and University of Modena and Reggio Emilia, Modena, Italy. marianna.meschiari1209@gmail.com.ORCID http://orcid.org/0000-0002-1254-9995
Iacopo FranconiDepartment of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy.
Erica BaccaDepartment of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy.
Vincenzo BiancoInfectious Diseases Clinic, Università degli Studi Federico II, Naples, Italy.
Gabriella OrlandoInfectious Diseases Unit, Azienda Ospedaliero-Universitaria Policlinico and University of Modena and Reggio Emilia, Modena, Italy.
Gianluca CuomoInfectious Diseases Unit, Azienda Ospedaliero-Universitaria Policlinico and University of Modena and Reggio Emilia, Modena, Italy.
Andrea BediniInfectious Diseases Unit, Azienda Ospedaliero-Universitaria Policlinico and University of Modena and Reggio Emilia, Modena, Italy.
Cristina MussiniDepartment of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy. cristina.mussini@unimore.it.
University of Modena and Reggio Emilia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePost-neurosurgical infection caused by extensively drug resistant Pseudomonas aeruginosa (XDR-PA) are becoming a matter of great concern due to limited therapeutic options. Although not approved for these indications, the new BetaLactam-BetaLactamase Inhibitor combinations (BLBLIs) could represent a valid salvage treatment. We describe one nosocomial meningitis and two cervical osteomyelitis due to an XDR-PA who were treated with ceftazidime/avibactam (CZA) and ceftolozane/tazobactam (C/T) and review the literature.

methodsThe first and the third patients developed an osteomyelitis following cervical stabilization surgery due to an XDR-PA. Although the first patient started treatment with a high dose of C/T, resistance to C/T occurred, so therapy was switched to CZA plus aztreonam. The third patient switched to aztreonam plus CZA due to development of acute kidney injury during therapy with colistin. The second patient had an XDR-PA meningitis following the insertion of an external ventricular catheter and he was treated with C/T plus meropenem and amikacin.

resultsAll three cases reported were successfully conservatively treated thanks to the use of the new BLBLIs with different combinations. Only few experiences demonstrated an equally favorable outcome: one patient treated with C/T plus fosfomycin for otogenic meningitis caused by an XDR-PA and another case of XDR-PA post-surgical meningitis with CZA in combination with colistin. Finally, the combination of CZA plus aztreonam has proven to be effective on XDR-PA only in limited mostly in vitro studies.

conclusionThese recently developed antibiotics, C/T and CZA are promising and complementary therapy options against post-neurosurgical hard-to-treat P. aeruginosa infections. Further prospective real-life studies are required to validate these findings in this special setting.

Indexed as

CeftazidimePseudomonas InfectionsAnti-Bacterial AgentsAzabicyclo CompoundsCephalosporinsDrug CombinationsDrug Resistance, Multiple, BacterialHumansMaleMicrobial Sensitivity TestsPseudomonas aeruginosaTazobactamAnti-Bacterial AgentsavibactamAzabicyclo CompoundsCeftazidimeceftolozaneCephalosporinsDrug CombinationsTazobactamCeftazidime/avibactamCeftolozane/tazobactamCervical osteomyelitisExtensively drug resistant Pseudomonas aeruginosaMeningitis

Identifiers

PMID33074365
PMCPMC7569357
OpenAlexW3093362044

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.